Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

2 drugs protect hearing better than 1

24.02.2011
Whether on a battlefield, in a factory or at a rock concert, noise-induced hearing loss is one of the most common hazards people face.

Researchers at Washington University School of Medicine in St. Louis have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before they are exposed to loud noise. The drugs, already FDA-approved for other conditions, also treat hearing loss after noise exposure.

While both drugs are known to protect hearing on their own, this is the first study to test the two in combination.

"We found they have synergy," says Jianxin Bao, PhD, research associate professor of otolaryngology at the School of Medicine. "Two drugs at lower dosages can block more signaling pathways than one alone, improving results while reducing side effects. We got the idea from cancer and HIV studies that use multiple drugs at lower dosages."

Bao presented the work Feb. 21 in Baltimore at a meeting of the Association for Research in Otolaryngology.

In earlier work, Bao's group found that anticonvulsant drugs for treating epilepsy helped protect hearing in mice after exposure to loud noise. And other groups had determined that glucocorticoids, anti-inflammatory drugs often used to treat allergies and asthma, were also protective.

The reasons these drugs reduce noise-induced hearing loss are not well understood. But anticonvulsants are known to block calcium channels in nerve cells, and Bao's group speculates that the drug helps protect neuronal connections between hair cells and auditory neurons.

For this work, Bao and colleagues chose two drugs from the anti-epilepsy family and two from the glucocorticoid family.

"We picked drugs that have fewer side effects and that can be chronically used," says Bao, also associate professor of audiology and communication sciences.

To test each drug's ability to prevent hearing loss, they gave various doses to mice two hours before exposing them to noise. To test treatment, they administered the drugs to different groups of mice 24 hours after noise exposure.

Three of the four drugs showed increasing protection with higher doses. And two of the drugs in combination, the anticonvulsant zonisamide and the glucocorticoid methylprednisolone, showed comparable hearing protection at much lower doses than when administered alone.

While the drugs do not prevent all hearing loss following sustained exposure to noise at 110 decibels, or about the sound of a chain saw, they can significantly reduce the loss by about 10 to 30 decibels.

In other words, a mouse with normal hearing might be able to hear a sound at 30 decibels. After exposure to loud noise, that mouse might only hear sounds that reach 50 decibels. But if that mouse were treated, it might be able to hear sounds at 40 decibels. In humans, protecting 5 or 10 decibels makes a difference in being able to hear everyday speech.

Bao says their next step is to test the drugs in animals that model human hearing more closely.

Bao et al. "Development of a combination therapy for noise-induced hearing loss." Presented Feb. 21, 2011 at a meeting of the Association for Research in Otolaryngology.

This work was supported by the National Institute on Deafness and Other Communication Disorders.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Julia Evangelou Strait | EurekAlert!
Further information:
http://www.wustl.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>